Multiple cohort studies have found no increased risk of severe COVID-19 associated with any of the biologic classes, including Tumor Necrosis Factor (TNF) antagonist agents, integrin antagonists, and interleukin (IL)-12/23 inhibitors (Ungaro et al., 2022, Ungaro et al., 2021b; Lukin et al., 2020; Agrawal et al., 2021). The gene discussed is TNF; the disease is COVID-19.